vs

Side-by-side financial comparison of CTO Realty Growth, Inc. (CTO) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

CTO Realty Growth, Inc. is the larger business by last-quarter revenue ($41.2M vs $35.5M, roughly 1.2× RECURSION PHARMACEUTICALS, INC.). CTO Realty Growth, Inc. runs the higher net margin — 15.1% vs -304.2%, a 319.3% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 15.0%). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 19.5%).

Keller Williams Realty is an American technology and international real estate franchise with headquarters in Austin, Texas. It is the largest real estate franchise in the United States by sales volume as of 2022.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

CTO vs RXRX — Head-to-Head

Bigger by revenue
CTO
CTO
1.2× larger
CTO
$41.2M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+666.8% gap
RXRX
681.7%
15.0%
CTO
Higher net margin
CTO
CTO
319.3% more per $
CTO
15.1%
-304.2%
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
19.5%
CTO

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CTO
CTO
RXRX
RXRX
Revenue
$41.2M
$35.5M
Net Profit
$6.2M
$-108.1M
Gross Margin
59.8%
Operating Margin
175.0%
-304.8%
Net Margin
15.1%
-304.2%
Revenue YoY
15.0%
681.7%
Net Profit YoY
174.4%
39.6%
EPS (diluted)
$0.13
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTO
CTO
RXRX
RXRX
Q1 26
$41.2M
Q4 25
$38.3M
$35.5M
Q3 25
$37.8M
$5.2M
Q2 25
$37.6M
$19.2M
Q1 25
$35.8M
$14.7M
Q4 24
$35.7M
$4.5M
Q3 24
$31.8M
$26.1M
Q2 24
$28.8M
$14.4M
Net Profit
CTO
CTO
RXRX
RXRX
Q1 26
$6.2M
Q4 25
$28.3M
$-108.1M
Q3 25
$2.9M
$-162.3M
Q2 25
$-23.4M
$-171.9M
Q1 25
$2.3M
$-202.5M
Q4 24
$-15.2M
$-178.9M
Q3 24
$6.2M
$-95.8M
Q2 24
$1.2M
$-97.5M
Gross Margin
CTO
CTO
RXRX
RXRX
Q1 26
Q4 25
75.0%
59.8%
Q3 25
75.4%
-183.8%
Q2 25
73.0%
-4.9%
Q1 25
75.2%
-48.0%
Q4 24
74.4%
-181.4%
Q3 24
74.4%
53.7%
Q2 24
71.1%
36.2%
Operating Margin
CTO
CTO
RXRX
RXRX
Q1 26
175.0%
Q4 25
75.1%
-304.8%
Q3 25
26.6%
-3327.6%
Q2 25
-33.7%
-916.8%
Q1 25
22.0%
-1297.9%
Q4 24
-20.4%
-4042.4%
Q3 24
15.6%
-377.1%
Q2 24
18.8%
-697.4%
Net Margin
CTO
CTO
RXRX
RXRX
Q1 26
15.1%
Q4 25
73.9%
-304.2%
Q3 25
7.7%
-3135.3%
Q2 25
-62.2%
-894.2%
Q1 25
6.3%
-1373.3%
Q4 24
-42.6%
-3935.5%
Q3 24
19.6%
-367.5%
Q2 24
4.1%
-676.6%
EPS (diluted)
CTO
CTO
RXRX
RXRX
Q1 26
$0.13
Q4 25
$0.81
$-0.17
Q3 25
$0.03
$-0.36
Q2 25
$-0.77
$-0.41
Q1 25
$0.01
$-0.50
Q4 24
$-0.69
$-0.56
Q3 24
$0.17
$-0.34
Q2 24
$-0.03
$-0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTO
CTO
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$8.3M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$575.4M
$1.1B
Total Assets
$1.3B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTO
CTO
RXRX
RXRX
Q1 26
$8.3M
Q4 25
$6.5M
$743.3M
Q3 25
$9.3M
$659.8M
Q2 25
$8.6M
$525.1M
Q1 25
$8.4M
$500.5M
Q4 24
$9.0M
$594.4M
Q3 24
$8.2M
$427.6M
Q2 24
$4.8M
$474.3M
Total Debt
CTO
CTO
RXRX
RXRX
Q1 26
Q4 25
$616.3M
$9.6M
Q3 25
$604.2M
$11.9M
Q2 25
$605.4M
$14.2M
Q1 25
$602.2M
$16.4M
Q4 24
$519.0M
$19.0M
Q3 24
$526.8M
$20.5M
Q2 24
$482.7M
$22.9M
Stockholders' Equity
CTO
CTO
RXRX
RXRX
Q1 26
$575.4M
Q4 25
$567.3M
$1.1B
Q3 25
$557.3M
$1.0B
Q2 25
$574.1M
$919.1M
Q1 25
$593.9M
$933.9M
Q4 24
$612.8M
$1.0B
Q3 24
$595.8M
$524.6M
Q2 24
$491.8M
$584.4M
Total Assets
CTO
CTO
RXRX
RXRX
Q1 26
$1.3B
Q4 25
$1.3B
$1.5B
Q3 25
$1.2B
$1.4B
Q2 25
$1.2B
$1.3B
Q1 25
$1.2B
$1.3B
Q4 24
$1.2B
$1.4B
Q3 24
$1.2B
$726.5M
Q2 24
$1.0B
$775.9M
Debt / Equity
CTO
CTO
RXRX
RXRX
Q1 26
Q4 25
1.09×
0.01×
Q3 25
1.08×
0.01×
Q2 25
1.05×
0.02×
Q1 25
1.01×
0.02×
Q4 24
0.85×
0.02×
Q3 24
0.88×
0.04×
Q2 24
0.98×
0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTO
CTO
RXRX
RXRX
Operating Cash FlowLast quarter
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTO
CTO
RXRX
RXRX
Q1 26
Q4 25
$64.6M
$-46.1M
Q3 25
$25.5M
$-117.4M
Q2 25
$21.9M
$-76.4M
Q1 25
$10.3M
$-132.0M
Q4 24
$59.9M
$-115.4M
Q3 24
$21.2M
$-59.2M
Q2 24
$12.9M
$-82.2M
Free Cash Flow
CTO
CTO
RXRX
RXRX
Q1 26
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
FCF Margin
CTO
CTO
RXRX
RXRX
Q1 26
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Capex Intensity
CTO
CTO
RXRX
RXRX
Q1 26
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Cash Conversion
CTO
CTO
RXRX
RXRX
Q1 26
Q4 25
2.28×
Q3 25
8.75×
Q2 25
Q1 25
4.56×
Q4 24
Q3 24
3.40×
Q2 24
10.89×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons